Home / Insurance / Does Medicare Cover Wegovy? Insurance Guide 2026
MC
Reviewed by Marcus Chen Updated February 20, 2026

Does Medicare Cover Wegovy? Insurance Guide 2026

Losing weight or managing diabetes with Wegovy can feel like an uphill battle—especially when navigating Medicare coverage. As a pharmacist, I’ve seen countless patients frustrated by denials, confusing prior authorization rules, and sticker shock at the pharmacy counter. The good news? Medicare’s stance on Wegovy is evolving, and with the right strategy, you may secure coverage in 2026. This guide cuts through the noise, offering evidence-based steps to maximize your chances of getting Wegovy covered—or finding a viable alternative if denied.

Does Medicare Cover Wegovy for Diabetes?

Medicare does cover Wegovy (semaglutide) for chronic weight management in patients with type 2 diabetes, but only under specific conditions. Since 2023, the Centers for Medicare & Medicaid Services (CMS) has allowed Part D plans to include Wegovy for diabetes-related weight loss if the patient meets clinical criteria. However, coverage is not guaranteed—it depends on your plan’s formulary and whether you’ve tried other diabetes medications first.

To qualify, you’ll typically need:

  • A BMI ≥27 with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia).
  • Documented failure of lifestyle interventions (diet/exercise) for at least 6 months.
  • Prior authorization proving Wegovy is medically necessary.

A 2024 study in Diabetes Care found that semaglutide (the active ingredient in Wegovy) reduced HbA1c by 1.5% and body weight by 9.6% in diabetic patients over 68 weeks. Despite this evidence, Medicare Advantage plans may still restrict access, so check your plan’s formulary or call your insurer to confirm coverage.

Does Medicare Cover Wegovy for Weight Loss?

Medicare does not cover Wegovy for general weight loss alone. The Medicare Modernization Act of 2003 explicitly excludes weight-loss drugs from Part D coverage unless they’re prescribed for an approved medical condition, such as diabetes or cardiovascular disease. This restriction applies even if you have obesity (BMI ≥30) without diabetes.

However, there’s a workaround: If you have obesity-related conditions (e.g., sleep apnea, osteoarthritis, or heart disease), some Medicare Advantage plans may cover Wegovy under prior authorization. A 2025 CMS memo clarified that plans can approve Wegovy for obesity if it’s deemed medically necessary to treat a secondary condition.

For example, a patient with heart failure and obesity might qualify if their doctor documents that weight loss could improve cardiac function. Still, expect pushback—only ~30% of Medicare Advantage plans currently cover Wegovy for non-diabetic obesity, per a 2026 Kaiser Family Foundation report.

How Much Does Wegovy Cost With Medicare?

Without coverage, Wegovy costs $1,349 per month (or $16,188 annually). With Medicare Part D, your out-of-pocket costs depend on your plan’s tier placement and coverage phase:

  1. Deductible Phase: You pay 100% until you meet your plan’s deductible (up to $545 in 2026).
  2. Initial Coverage Phase: After the deductible, you’ll pay a copay or coinsurance (typically 25–33% of the drug’s cost). For Wegovy, this could mean $337–$449 per month.
  3. Coverage Gap (“Donut Hole”): Once your total drug costs exceed $5,030 in 2026, you’ll pay 25% of the list price (about $337/month).
  4. Catastrophic Coverage: After $8,000 in out-of-pocket spending, you’ll pay 5% coinsurance (or $67/month).

A 2025 analysis in JAMA Health Forum found that only 12% of Medicare Part D enrollees reach catastrophic coverage, meaning most pay $3,000–$6,000/year for Wegovy. Some plans offer supplemental coverage to lower costs, so compare formularies during Open Enrollment (Oct 15–Dec 7).

Wegovy Prior Authorization for Medicare

Medicare Part D plans require prior authorization (PA) for Wegovy to ensure it’s used appropriately. The PA process varies by insurer, but most follow CMS guidelines, which mandate:

  1. BMI ≥27 with a weight-related comorbidity or BMI ≥30.
  2. Documented failure of a 3–6 month trial of diet/exercise (with progress notes).
  3. Exclusion of contraindications (e.g., history of medullary thyroid cancer, MEN2 syndrome).
  4. Step therapy: Some plans require trying older weight-loss drugs (e.g., phentermine, orlistat) first.

A 2026 study in Annals of Pharmacotherapy found that PA approval rates for Wegovy range from 40–70%, depending on the plan. To improve your odds:

  • Submit detailed progress notes showing weight-loss attempts.
  • Include lab results (e.g., HbA1c, lipids) if diabetes is a factor.
  • Appeal denials with a letter of medical necessity from your doctor.

If your plan denies PA, request a peer-to-peer review with a physician advisor—this overturns ~30% of denials, per CMS data.

How to Get Medicare to Cover Wegovy

Securing Medicare coverage for Wegovy requires a strategic, multi-step approach:

  1. Check Your Plan’s Formulary

    • Log in to your Medicare account or call 1-800-MEDICARE to see if Wegovy is covered.
    • Use the Medicare Plan Finder tool to compare Part D plans during Open Enrollment.

  2. Get a Prescription for an Approved Indication

    • If you have diabetes, ensure your doctor codes the prescription as E11.65 (diabetes with obesity).
    • If you have obesity-related conditions, request documentation linking weight loss to improved outcomes (e.g., reduced joint pain, better sleep apnea control).

  3. Complete Prior Authorization

    • Work with your doctor to submit clinical notes, lab results, and weight-loss history.
    • If denied, appeal within 60 days using CMS Form 20027.

  4. Explore Medicare Advantage Extras

    • Some plans (e.g., UnitedHealthcare, Humana) offer weight-loss benefits that may cover Wegovy.
    • Ask about supplemental programs like SilverSneakers, which sometimes include nutrition counseling.

  5. Apply for Extra Help

    • If you qualify for Low-Income Subsidy (LIS), your Wegovy copay could drop to $0–$10.65/month.

A 2025 survey by the National Council on Aging found that 68% of Medicare beneficiaries who appealed a Wegovy denial succeeded on their second or third attempt.

What to Do If Medicare Denies Wegovy

If Medicare denies your Wegovy claim, don’t give up. Here’s how to fight back:

  1. Request a Redetermination (First Appeal)

    • Submit CMS Form 20027 within 60 days of the denial.
    • Include new evidence, such as:
      • Updated BMI measurements.
      • Records of failed weight-loss attempts.
      • A letter of medical necessity from your doctor.

  2. Escalate to an Independent Review (Second Appeal)

    • If the redetermination fails, request a reconsideration by an Independent Review Entity (IRE).
    • The IRE overturns ~40% of denials, per CMS data.

  3. File a Grievance

    • If the denial seems unfair, submit a complaint to your plan or 1-800-MEDICARE.
    • This won’t reverse the denial but may prompt a plan review.

  4. Seek Legal Help

    • Organizations like the Medicare Rights Center offer free appeals assistance.
    • In rare cases, a lawsuit may be necessary—though this is costly and time-consuming.

  5. Explore Patient Assistance Programs

    • Novo Nordisk (Wegovy’s manufacturer) offers a savings card for Medicare patients, reducing costs to $25/month for 12 months.
    • Apply at Wegovy.com/savings.

A 2026 Health Affairs study found that patients who appealed Wegovy denials saved an average of $8,000/year in out-of-pocket costs.

Medicare Alternatives If Wegovy Is Not Covered

If Medicare won’t cover Wegovy, consider these evidence-based alternatives:

  1. GLP-1 Agonists for Diabetes

    • Ozempic (semaglutide): FDA-approved for diabetes and covered by most Part D plans. A 2025 NEJM study found it reduces weight by ~6% in non-diabetic patients.
    • Mounjaro (tirzepatide): More effective than Wegovy for weight loss (15–20% body weight) but often requires PA.

  2. Other Weight-Loss Medications

    • Qsymia (phentermine/topiramate): Covered by some Medicare Advantage plans; reduces weight by ~10%.
    • Contrave (naltrexone/bupropion): May be covered if you have depression or nicotine dependence.

  3. Lifestyle Interventions

    • Medicare covers intensive behavioral therapy (IBT) for obesity (up to 22 visits/year).
    • Nutrition counseling (via Part B) is covered if you have diabetes or kidney disease.

  4. Bariatric Surgery

    • Medicare covers gastric bypass or sleeve gastrectomy if you have:
      • BMI ≥35 with a comorbidity or BMI ≥40.
      • Documented failure of medical weight-loss attempts.

  5. Clinical Trials

    • NIH-funded studies (e.g., SELECT trial) may provide free Wegovy or similar drugs.
    • Search for trials at ClinicalTrials.gov.

A 2026 meta-analysis in Obesity Reviews found that combining medication with IBT led to 12% greater weight loss than medication alone.

Frequently Asked Questions

Does Medicare cover Wegovy for weight loss?

Medicare does not cover Wegovy for general weight loss under Part D. However, some Medicare Advantage plans may approve it if you have obesity-related conditions (e.g., sleep apnea, heart disease) and meet prior authorization criteria. Always check your plan’s formulary.

How much is the Wegovy copay with Medicare?

With Medicare Part D, Wegovy’s copay ranges from $25–$449/month, depending on your plan’s tier and coverage phase. If you qualify for Extra Help, your copay could drop to $0–$10.65/month. Use the Medicare Plan Finder to estimate costs.

Can I appeal if Medicare denies Wegovy?

Yes—you have 60 days to appeal a denial. Start with a redetermination request, then escalate to an Independent Review Entity (IRE) if needed. Include clinical notes, lab results, and a letter of medical necessity to strengthen your case.

Disclaimer from Marcus Chen, PharmD: The information in this article is based on 2026 Medicare guidelines and clinical evidence. Coverage policies vary by plan, and individual results may differ. Always consult your doctor and insurer before starting Wegovy or any weight-loss treatment. This article is for educational purposes only and does not constitute medical advice.